Jeri Sue Plaxco on Muck Rack

Jeri Sue Plaxco

As seen in: ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jeri Sue

Contact Jeri Sue, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

53 U.S. Patient Perspectives on Capivasertib Plus Fulvestrant: Dosing, Tolerability, and Blood Glucose Monitoring From Qualitative Interviews

|
By Gabriella Kaddu, Jeri Sue Plaxco, Umberto Gianni
| ONCOLOGY journal Verified
Background Capivasertib, an AKT inhibitor, is administered on a 4-days-on/3-days-off schedule (4-on/3-off) and requires fasting glucose monitoring due to the risk of hyperglycemia, a known on-target effect of PI3K/AKT pathway inhibition. Real-world patient perspectives on treatment experience can inform patient education and supportive care.
Open in Who Shared Issue with article?

Jeri Sue Plaxco | Authors | CancerNetwork

|
By Jeri Sue Plaxco
| ONCOLOGY journal Verified
Articles by Jeri Sue Plaxco This 13-case pictorial review from the University of Rochester Medical Center illustrates the variable mammography, ultrasound, and MRI presentations of pleomorphic invasive lobular carcinoma to support timely interdisciplinary diagnosis.
Open in Who Shared View Duplicates (2) Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified